{"entity":{"id":"nct07235930","kind":"trial","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of bevacizumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Zhejiang Cancer Hospital, now recruiting.","summary":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT07235930 by Zhejiang Cancer Hospital, with a registry enrolment figure of 292 participants, started 2025-11-15 and due to reach its primary completion in 2029-07-01. Interventions recorded: Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab; AG chemotherapy. Conditions listed: Non-Resectable Pancreas Carcinoma. Primary outcome: Overall survival (OS). Pancreatic eligibility wording from the registry: \"Pancreatic ductal adenocarcinoma confirmed by pathologic histology or cytology;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07235930","url":"https://clinicaltrials.gov/study/NCT07235930"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["bevacizumab","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07235930","phase":"3","setting":"Nab-Paclitaxel/Gemcitabine Followed by mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Previously Untreated Advanced Pancreatic Cancer: A Randomized, Controlled, Multicenter Phase III Trial","sponsor":"Zhejiang Cancer Hospital","enrolled":292,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07235930/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}